Complete responder versus noncomplete responder characteristics at baseline
| n | Complete responders (n=289) | n | Noncomplete responders (n=213) | p-value | |
| Age, years | 289 | 58±12 | 213 | 56±13 | 0.12 |
| Female | 289 | 129 (45) | 213 | 115 (54) | 0.038 |
| BMI, kg·m−2 | 287 | 28±5 | 211 | 28±6 | 0.28 |
| Duration of disease, years | 179 | 20±17 | 129 | 24±19 | 0.04 |
| Duration of disease >10 years | 179 | 107 (60) | 129 | 87 (67) | 0.169 |
| Age at onset, years | 179 | 38±20 | 129 | 32±21 | 0.02 |
| Onset during childhood ≤18 years | 186 | 46 (25) | 135 | 47 (35) | 0.131 |
| Late onset ≥40 years | 186 | 90 (48) | 135 | 54 (40) | 0.131 |
| Exacerbations in year before biologic, n | 219 | 2.80±2.61 | 172 | 3.43±3.61 | 0.049 |
| Budesonide-equivalent dose, µg | 195 | 1600 (1200–1600) | 155 | 1600 (1600–2000) | 0.23 |
| mOCS | 289 | 52 (18) | 213 | 134 (63) | <0.0001 |
| Median dose, mg | 46 | 7.5 (5–10) | 91 | 10 (7.5–15) | 0.03 |
| Biologic | 289 | 213 | 0.125 | ||
| Mepolizumab | 207 (72) | 148 (69) | |||
| Reslizumab | 10 (3) | 16 (8) | |||
| Benralizumab | 72 (25) | 49 (23) | |||
| Switchers | 289 | 66 (23) | 213 | 63 (29) | 0.08 |
| FEV1, L | 248 | 2.26±0.85 | 188 | 2.18±0.83 | 0.31 |
| FEV1, % pred | 246 | 70±21 | 186 | 68±21 | 0.41 |
| FEV1/FVC | 237 | 0.64±0.13 | 184 | 0.65±0.13 | 0.70 |
| ACQ score | 168 | 2.32±1.32 | 144 | 2.67±1.24 | 0.01 |
| Blood eosinophils, ×109 L−1 | 234 | 0.40 (0.18–0.65) | 181 | 0.23 (0.1–0.54) | 0.0002 |
| Blood eosinophils ≥0.3×109 L−1 | 234 | 146 (62) | 181 | 81 (45) | 0.0003 |
| IgE, IU·mL−1 | 146 | 141 (66–399) | 112 | 70 (54–83) | 0.09 |
| IgE ≥150 IU·mL−1 | 146 | 71 (49) | 112 | 48 (43) | 0.35 |
| FENO, ppb | 201 | 32 (18–64) | 151 | 32 (14–63) | 0.65 |
| Smoking status | 281 | 205 | 0.62 | ||
| Never-smoker | 151 (54) | 101 (49) | |||
| Ex-smoker | 125 (44) | 100 (49) | |||
| Current smoker | 5 (2) | 4 (2) | |||
| Pack-years | 15.9±13 | 17.7±14.4 | 0.33 | ||
| Allergic rhinitis | 277 | 132 (48) | 203 | 82 (41) | 0.11 |
| Atopic dermatitis | 274 | 37 (14) | 202 | 26 (13) | 0.84 |
| Chronic rhinosinusitis | 273 | 166 (61) | 201 | 109 (54) | 0.15 |
| Nasal polyps | 276 | 122 (44) | 202 | 86 (43) | 0.72 |
| Aspirin sensitivity | 274 | 27 (10) | 201 | 12 (6) | 0.13 |
| Bronchiectasis | 276 | 53 (19) | 202 | 46 (23) | 0.34 |
| Vocal cord dysfunction | 272 | 5 (2) | 199 | 5 (3) | 0.61 |
| ABPA | 275 | 9 (3) | 200 | 5 (3) | 0.62 |
| EGPA | 273 | 11 (4) | 200 | 9 (5) | 0.80 |
| Dysfunctional breathing | 273 | 17 (6) | 201 | 10 (5) | 0.56 |
| COPD | 270 | 61 (23) | 200 | 55 (28) | 0.22 |
| GORD | 272 | 83 (31) | 202 | 63 (31) | 0.87 |
| Cardiovascular disease | 274 | 82 (30) | 201 | 67 (33) | 0.42 |
| Diabetes | 275 | 25 (9) | 202 | 30 (15) | 0.05 |
| OSA | 273 | 26 (10) | 202 | 29 (14) | 0.10 |
Data are presented as mean±sd, n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; mOCS: maintenance oral corticosteroids; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; FENO: exhaled nitric oxide fraction; ABPA: allergic bronchopulmonary aspergillosis; EGPA: eosinophilic granulomatosis with polyangiitis; COPD: chronic obstructive pulmonary disease; GORD: gastro-oesophageal reflux disease; OSA: obstructive sleep apnoea.